Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
about
Harnessing the immune system to improve cancer therapyOvercoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint BlockadeExploring Reovirus Plasticity for Improving Its Use as Oncolytic VirusOncolytic adenovirus-mediated therapy for prostate cancerViruses as nanomedicine for cancerTrial Watch-Oncolytic viruses and cancer therapyHarnessing the Power of Onco-Immunotherapy with Checkpoint InhibitorsOncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesOncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.Immunotherapy for Esophageal Squamous Cell Carcinoma.Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes.Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy.Oncolytic Viral Therapy for Mesothelioma.Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions.Prospects for combined use of oncolytic viruses and CAR T-cells.Oncolytic Virotherapy and the Tumor Microenvironment.Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model.Mechanisms regulating T-cell infiltration and activity in solid tumors.Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus.Viroimmunotherapy for Colorectal Cancer: Clinical Studies.Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
P2860
Q26738698-22D407C7-D688-45D6-A590-779653DD7435Q26769977-CC20088D-279C-47FA-90D6-AC243EDC1A96Q26771799-2C9A7ADC-1E2F-4BC4-8801-F2F76EFF30F2Q27004796-680BEC29-E69C-418A-AE8A-6451B3CC6111Q27690636-F9BBCDA7-89C3-4845-812B-85EA766CCA7BQ28072347-DF685F3E-A7BA-44B2-A857-E6CF92BC6877Q28086999-73D9A15C-F3D9-4CEE-BD90-4435E3F9DAEBQ33679505-8A81910C-3E72-4AF7-94C5-ED247BEEEB51Q33899522-A802CBA2-21F0-4B49-8BFC-0B3914A002F1Q37380398-192295A9-0513-4A12-B076-D5E0BAFC468BQ37651860-B5D78CB2-36C2-4E3A-BF3A-63D2FC19A74AQ37730966-2DA2B28B-EA27-470E-9C10-9E494826B06CQ38673968-549CD15D-2675-4EEA-A7F8-5CCE979AE3EEQ38746023-271E6229-121C-4136-BE5B-985CA48AE00CQ38790788-B510E229-21BC-45E1-ABBF-56548CE93A81Q38924557-5413837F-B70F-452A-9F63-CDBF8B7C16FBQ39427382-EB0CD7F6-FA75-4542-ABAD-1A0426927450Q40051845-86A9FE27-66D6-4F23-945C-0094BF3B54A9Q40082476-492481A7-43BB-4B9A-B7DA-F3FF4B7D058CQ40104793-47CF3212-8519-4CF2-85DA-D26EA598611FQ41706961-B3673D9F-3B74-48DD-9417-46463AFF64B6Q42375643-D3593677-9153-4051-B1D9-9E9BB9164DC6Q47103891-58CD9E34-F64F-4907-BB6E-8EDF37D3563CQ47560690-0916E808-2994-40F3-9242-3578F398E4A3Q50053595-5FD3E84A-8224-4A42-862D-244234815701Q50089395-E3F88B69-D6A1-44B6-8407-46A1B167BE97Q50865520-6C1A4CB4-5E76-4D34-BB3B-7B9F7A065AC6Q54218762-B1BBF88D-1C49-4D0E-ACA0-303E62B10896Q54221621-FC9D6233-FB18-44B8-B25A-483C3D212C67Q54378300-3BC7A72C-9693-4F2F-A85C-53846E99504FQ55051893-20479804-052B-4ABC-AEB9-70A644C3FF8BQ55085114-B44ECD7E-AA7B-46CA-8D21-67AD77146A04Q55085319-3BD62222-720C-432B-815A-AC7A0B3EB5C9Q55509278-52D4A3B7-C241-4C35-90CC-D7BCD18B36DDQ58572502-6C9589E2-D925-4765-9D9C-CEEB188F0C5D
P2860
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
@ast
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
@en
type
label
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
@ast
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
@en
prefLabel
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
@ast
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
@en
P2093
P2860
P1476
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
@en
P2093
Juan J Rojas
Steve H Thorne
Weizhou Hou
P2860
P304
P356
10.1158/1078-0432.CCR-14-2009
P407
P577
2015-07-17T00:00:00Z